Drugs / ZN-c5
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04852419 | May 2021 → Jun 2022 | breast cancer | Zentera Therapeutics HK Limited | Completed | No outcome recorded |
| Phase 1 | NCT04514159 | Nov 2020 → Oct 2022 | breast cancer | Zeno Alpha Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04561752 | Nov → Dec 2020 | — | Zeno Alpha Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04176757 | Jan 2020 → Apr 2021 | breast cancer | Zeno Alpha Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03560531 | Nov 2018 → Apr 2022 | breast cancer | Zeno Alpha Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-06-28 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals Announces Updates Across Its Pipeline Including Promising New Interim Clinical Data On Zn-C3 (Wee1I) And Zn-C5 (Serd) And Two Potentially Registrational Trials For Zn-C3, With The First Trial Already Initiated zentalis.com ↗
Interim data from ZN-c5 Phase 1 clinical trial supports its potential best-in-class safety and tolerability profiles in monotherapy and in combinations |
| 2020-06-15 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals To Present Preclinical Data On Zn-C5 At The Upcoming Aacr Virtual Annual Meeting II zentalis.com ↗
The preclinical data demonstrated that ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, had antitumor activity in human tumor breast cancer xenograft models. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-06-28 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Zentalis Pharmaceuticals Announces Updates Across Its Pipeline Including Promising New Interim Clinical Data On Zn-C3 (Wee1I) And Zn-C5 (Serd) And Two Potentially Registrational Trials For Zn-C3, With The First Trial Already Initiated zentalis.com ↗ |
| 2020-07-27 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Zentalis Pharmaceuticals Enters Into Clinical Collaboration With Eli Lilly And Company To Evaluate Its Oral Serd Zn-C5 In Combination With Abemaciclib, A Cdk4 And 6 Inhibitor zentalis.com ↗ |
| 2020-06-15 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Zentalis Pharmaceuticals To Present Preclinical Data On Zn-C5 At The Upcoming Aacr Virtual Annual Meeting II zentalis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZN-c5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03560531 ↗ |
| Route | Oral | “ZN-c5 administered orally” NCT03560531 ↗ |